Vir Biotechnology (Vir Biotechnology) Revenue per Share

: $0.30 (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

Vir Biotechnology's revenue per share for the three months ended in Dec. 2023 was $0.07. Vir Biotechnology's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.30.

Warning Sign:

Vir Biotechnology Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue Per Share Growth Rate of Vir Biotechnology was -97.50% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -19.50% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 203.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Vir Biotechnology's Revenue per Share or its related term are showing as below:

VIR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -19.5 Med: 627.3 Max: 867.4
Current: -19.5

During the past 7 years, Vir Biotechnology's highest 3-Year average Revenue Per Share Growth Rate was 867.40% per year. The lowest was -19.50% per year. And the median was 627.30% per year.

VIR's 3-Year Revenue Growth Rate is ranked worse than
77.44% of 767 companies
in the Biotechnology industry
Industry Median: 4.7 vs VIR: -19.50

Vir Biotechnology Revenue per Share Historical Data

The historical data trend for Vir Biotechnology's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vir Biotechnology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Revenue per Share

Get a 7-Day Free Trial

0.02

0.56

8.15

11.72

0.29

Vir Biotechnology Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Revenue per Share	Get a 7-Day Free Trial															0.16	0.35	-0.10	-0.03	0.07

Competitive Comparison

For the Biotechnology subindustry, Vir Biotechnology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vir Biotechnology PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Vir Biotechnology's PS Ratio distribution charts can be found below:

* The bar in red indicates where Vir Biotechnology's PS Ratio falls into.

Vir Biotechnology Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Vir Biotechnology's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )	=	Revenue (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	39.494	/	134.131
	=	0.29

Vir Biotechnology's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )	=	Revenue (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	9.602	/	134.614
	=	0.07

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.30

Vir Biotechnology (NAS:VIR) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Vir Biotechnology Revenue per Share Related Terms

Thank you for viewing the detailed overview of Vir Biotechnology's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Vir Biotechnology (Vir Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vir Biotechnology Inc (NAS:VIR) » Definitions » Revenue per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

499 Illinois Street, Suite 500, San Francisco, CA, USA, 94158

Website

https://www.vir.bio

Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Executives

Svf Endurance (cayman) Ltd	10 percent owner	C/O WALKERS CORPORATE LIMITED, 27 HOSPITAL ROAD, GEORGE TOWN E9 KY1-9008
Vicki L Sato	director	940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Phillip Pang	officer: Chief Medical Officer	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Steven J. Rice	officer: Chief Administrative Officer	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Backer Marianne De	officer: Chief Executive Officer	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Ann M. Hanly	officer: Chief Technology Officer	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Sung Lee	officer: Chief Financial Officer	7000 MARINA BLVD, BRISBANE CA 94005
Johanna Friedl-naderer	officer: Chief Business Officer, Global	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
George A Scangos	director, officer: President and CEO	C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Howard Horn	officer: CFO	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Charles Elliott Sigal	director	32 BREARLY ROAD, PRINCETON NJ 08540
Herbert Virgin	officer: EVP, Research & CSO	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Janet Napolitano	director	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Robert J More	director	680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001